Karyopharm's Xpovio Fails Phase 3 Trial for Endometrial Cancer, Shares Plummet
Karyopharm Therapeutics (NASDAQ: KPTI) reported that its drug Xpovio failed to meet the primary endpoint in a phase 3 clinical trial for endometrial cancer. The study showed no significant difference in progression-free survival between patients treated with Xpovio and those receiving standard care, leading to an approximately 69% drop in after-hours trading. The failure of this key trial has raised concerns about the drug's efficacy in treating TP53 wild-type advanced endometrial cancer. This setback could impact Karyopharm’s future revenue projections from Xpovio and may affect investor confidence in its pipeline for other indications.
Tickers: $KPTI
Topics: cancer_treatment pharma stock_movement